Protalix BioTherapeutics, Inc.

AMEX (USD): Protalix BioTherapeutics, Inc. (PLX)

Last Price

1.69

Today's Change

+0.03 (1.80%)

Day's Change

1.66 - 1.78

Trading Volume

545,501

Financial

T4Q

31-Mar-2021

2020

31-Mar-2021

2019

31-Mar-2021

2018

31-Mar-2021

2017

31-Mar-2021

Total assets

238

-1.64%

1000

+11.55%

110

+81.66%

900

-13.16%

600

+235.36%

Total current assets

238

1000

110

900

600

Cash & equivalents

238

1000

110

900

600

Short term investments

238

1000

110

900

600

Total receivables, net

238

1000

110

900

600

Accounts receivable - trade, net

238

1000

110

900

600

Other receivables

238

1000

110

900

600

Total inventory

238

1000

110

900

600

Inventories - work in progress

238

1000

110

900

600

Inventories - progress payments & other

238

1000

110

900

600

Inventories - finished goods

238

1000

110

900

600

Inventories - raw materials

238

1000

110

900

600

Total non-current assets

238

1000

110

900

600

Long term investments

238

1000

110

900

600

Note receivable - long term

238

1000

110

900

600

Investments in unconsolidated subsidiaries

238

1000

110

900

600

Other investments

238

1000

110

900

600

Net property/plant/equipment

238

1000

110

900

600

Gross property/plant/equipment

238

1000

110

900

600

Accumulated depreciation, total

238

1000

110

900

600

Deferred tax assets

238

1000

110

900

600

Net intangible assets

238

1000

110

900

600

Other current assets, total

238

1000

110

900

600

Total liabilities

238

-1.64%

1000

+11.55%

110

+81.66%

900

-13.16%

600

+235.36%

Total current liabilities

-238

-1000

-110

-900

-600

Total non-current liabilities

-238

-1000

-110

-900

-600

Long term debt

238

1000

110

900

600

Long term debt excl. lease liabilities

238

1000

110

900

600

Capital and operating lease obligations

238

1000

110

900

600

Provision for risks & charge

-238

-1000

-110

-900

-600

Deferred tax liabilities

-238

-1000

-110

-900

-600

Other liabilities, total

-238

-1000

-110

-900

-600

Total equity

-238

-1.64%

-1000

+11.55%

-110

+81.66%

-900

-13.16%

-600

+235.36%

Total liabilities & shareholders' equities

238B

1000B

110B

900B

600B

Total debt

238

1000

110

900

600

Book value per share

-238

-1000

-110

-900

-600

Discussions
Be the first to like this. Showing 3 of 3 comments

ysabag

with the new ceo it will raise above the target

2014-07-29 14:51

Tygobar

Yes, medical startups usually should very very good in everything like that really and totally , yet you do have very low price of the stock here, how can you really even describe this ? Could you damn let me know this please. I am all ears for example.

2019-09-01 13:12

Lalis

I do hope that medical things will be really our future and not just cause it cause something for example good for now, but in the real perspective for many many generations ahead totally. But for now of course I plan to invest a lot in such things.

2019-09-07 13:56

Post a Comment